(PODD) Insulet - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US45784P1012
Stock: Insulin Pumps, Diabetes Management, Drug Delivery
Total Rating 47
Risk 84
Buy Signal -0.20
| Risk 5d forecast | |
|---|---|
| Volatility | 35.8% |
| Relative Tail Risk | -9.04% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.03 |
| Alpha | -23.48 |
| Character TTM | |
|---|---|
| Beta | 0.760 |
| Beta Downside | 1.309 |
| Drawdowns 3y | |
|---|---|
| Max DD | 61.31% |
| CAGR/Max DD | -0.12 |
EPS (Earnings per Share)
Revenue
Description: PODD Insulet March 03, 2026
Insulet Corporation specializes in the development and manufacture of tubeless insulin delivery systems, primarily through its Omnipod product line. Its flagship offerings include the Omnipod 5, an automated insulin delivery system that integrates with continuous glucose monitors via Bluetooth, and the Omnipod DASH system. Beyond diabetes care, the company adapts its wearable technology for non-insulin drug delivery, such as the Neulasta Onpro kit used in oncology.
The company operates within the medical device sector, utilizing a recurring revenue business model driven by the continuous need for disposable pods. Unlike traditional durable insulin pumps that require multi-year commitments, Insulet frequently distributes its products through the pharmacy channel, lowering the initial cost barrier for patients and increasing market accessibility. For a deeper look into the companys valuation metrics, you may want to explore ValueRay.
Headquartered in Acton, Massachusetts, Insulet maintains a global presence, selling to end-users both directly and through independent distributors. This dual focus on automated glucose management and strategic pharmaceutical partnerships positions the firm as a key player in the evolving landscape of wearable healthcare technology.
Headlines to watch out for
- Omnipod 5 adoption drives revenue growth
- Competition intensifies in automated insulin delivery market
- Regulatory approvals impact product launch timelines
- Reimbursement policies affect patient access and sales
- Manufacturing costs influence profit margins
Piotroski VR‑10 (Strict, 0-10) 9.0
| Net Income: 247.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 2.40 > 1.0 |
| NWC/Revenue: 44.63% < 20% (prev 64.82%; Δ -20.19% < -1%) |
| CFO/TA 0.18 > 3% & CFO 569.3m > Net Income 247.1m |
| Net Debt (334.7m) to EBITDA (486.6m): 0.69 < 3 |
| Current Ratio: 2.78 > 1.5 & < 3 |
| Outstanding Shares: last quarter (70.7m) vs 12m ago -4.61% < -2% |
| Gross Margin: 71.63% > 18% (prev 0.70%; Δ 7093 % > 0.5%) |
| Asset Turnover: 86.27% > 50% (prev 67.09%; Δ 19.18% > 0%) |
| Interest Coverage Ratio: 6.09 > 6 (EBITDA TTM 486.6m / Interest Expense TTM 64.0m) |
Altman Z'' 3.80
| A: 0.38 (Total Current Assets 1.89b - Total Current Liabilities 680.1m) / Total Assets 3.19b |
| B: 0.09 (Retained Earnings 287.4m / Total Assets 3.19b) |
| C: 0.12 (EBIT TTM 390.0m / Avg Total Assets 3.14b) |
| D: 0.18 (Book Value of Equity 300.7m / Total Liabilities 1.68b) |
| Altman-Z'' Score: 3.80 = AA |
Beneish M -2.91
| DSRI: 1.08 (Receivables 516.9m/365.5m, Revenue 2.71b/2.07b) |
| GMI: 0.97 (GM 71.63% / 69.79%) |
| AQI: 0.93 (AQ_t 0.14 / AQ_t-1 0.15) |
| SGI: 1.31 (Revenue 2.71b / 2.07b) |
| TATA: -0.10 (NI 247.1m - CFO 569.3m) / TA 3.19b) |
| Beneish M-Score: -2.91 (Cap -4..+1) = A |
What is the price of PODD shares?
As of March 10, 2026, the stock is trading at USD 240.38 with a total of 928,165 shares traded.
Over the past week, the price has changed by -2.07%, over one month by -2.11%, over three months by -18.29% and over the past year by +1.40%.
Over the past week, the price has changed by -2.07%, over one month by -2.11%, over three months by -18.29% and over the past year by +1.40%.
Is PODD a buy, sell or hold?
Insulet has received a consensus analysts rating of 4.43.
Therefore, it is recommended to buy PODD.
- StrongBuy: 14
- Buy: 6
- Hold: 2
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the PODD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 354.4 | 47.4% |
| Analysts Target Price | 354.4 | 47.4% |
PODD Fundamental Data Overview March 08, 2026
P/E Trailing = 68.3026
P/E Forward = 39.2157
P/S = 6.161
P/B = 11.2839
P/EG = 1.7119
Revenue TTM = 2.71b USD
EBIT TTM = 390.0m USD
EBITDA TTM = 486.6m USD
Long Term Debt = 930.8m USD (from longTermDebt, last quarter)
Short Term Debt = 22.2m USD (from shortTermDebt, last quarter)
Debt = 1.05b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 334.7m USD (from netDebt column, last quarter)
Enterprise Value = 17.02b USD (16.68b + Debt 1.05b - CCE 716.1m)
Interest Coverage Ratio = 6.09 (Ebit TTM 390.0m / Interest Expense TTM 64.0m)
EV/FCF = 45.06x (Enterprise Value 17.02b / FCF TTM 377.7m)
FCF Yield = 2.22% (FCF TTM 377.7m / Enterprise Value 17.02b)
FCF Margin = 13.95% (FCF TTM 377.7m / Revenue TTM 2.71b)
Net Margin = 9.12% (Net Income TTM 247.1m / Revenue TTM 2.71b)
Gross Margin = 71.63% ((Revenue TTM 2.71b - Cost of Revenue TTM 768.3m) / Revenue TTM)
Gross Margin QoQ = 72.54% (prev 72.22%)
Tobins Q-Ratio = 5.33 (Enterprise Value 17.02b / Total Assets 3.19b)
Interest Expense / Debt = 1.87% (Interest Expense 19.6m / Debt 1.05b)
Taxrate = 27.46% (38.5m / 140.2m)
NOPAT = 282.9m (EBIT 390.0m * (1 - 27.46%))
Current Ratio = 2.78 (Total Current Assets 1.89b / Total Current Liabilities 680.1m)
Debt / Equity = 0.69 (Debt 1.05b / totalStockholderEquity, last quarter 1.52b)
Debt / EBITDA = 0.69 (Net Debt 334.7m / EBITDA 486.6m)
Debt / FCF = 0.89 (Net Debt 334.7m / FCF TTM 377.7m)
Total Stockholder Equity = 1.42b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.87% (Net Income 247.1m / Total Assets 3.19b)
RoE = 17.36% (Net Income TTM 247.1m / Total Stockholder Equity 1.42b)
RoCE = 16.57% (EBIT 390.0m / Capital Employed (Equity 1.42b + L.T.Debt 930.8m))
RoIC = 10.52% (NOPAT 282.9m / Invested Capital 2.69b)
WACC = 8.28% (E(16.68b)/V(17.74b) * Re(8.72%) + D(1.05b)/V(17.74b) * Rd(1.87%) * (1-Tc(0.27)))
Discount Rate = 8.72% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.58%
[DCF] Terminal Value 68.94% ; FCFF base≈343.2m ; Y1≈225.3m ; Y5≈102.8m
[DCF] Fair Price = 22.44 (EV 1.91b - Net Debt 334.7m = Equity 1.58b / Shares 70.4m; r=8.28% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 82.16 | EPS CAGR: 40.72% | SUE: -0.09 | # QB: 0
Revenue Correlation: 98.48 | Revenue CAGR: 29.72% | SUE: 1.58 | # QB: 16
EPS next Quarter (2026-06-30): EPS=1.44 | Chg7d=-0.026 | Chg30d=+0.003 | Revisions Net=+4 | Analysts=22
EPS current Year (2026-12-31): EPS=6.35 | Chg7d=+0.010 | Chg30d=+0.166 | Revisions Net=+18 | Growth EPS=+27.7% | Growth Revenue=+22.0%
EPS next Year (2027-12-31): EPS=8.09 | Chg7d=+0.021 | Chg30d=+0.238 | Revisions Net=+18 | Growth EPS=+27.4% | Growth Revenue=+19.1%
[Analyst] Revisions Ratio: +0.22 (11 Up / 7 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 7.3% (Discount Rate 8.7% - Earnings Yield 1.5%)
[Growth] Growth Spread = +14.4% (Analyst 21.6% - Implied 7.3%)
P/E Forward = 39.2157
P/S = 6.161
P/B = 11.2839
P/EG = 1.7119
Revenue TTM = 2.71b USD
EBIT TTM = 390.0m USD
EBITDA TTM = 486.6m USD
Long Term Debt = 930.8m USD (from longTermDebt, last quarter)
Short Term Debt = 22.2m USD (from shortTermDebt, last quarter)
Debt = 1.05b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 334.7m USD (from netDebt column, last quarter)
Enterprise Value = 17.02b USD (16.68b + Debt 1.05b - CCE 716.1m)
Interest Coverage Ratio = 6.09 (Ebit TTM 390.0m / Interest Expense TTM 64.0m)
EV/FCF = 45.06x (Enterprise Value 17.02b / FCF TTM 377.7m)
FCF Yield = 2.22% (FCF TTM 377.7m / Enterprise Value 17.02b)
FCF Margin = 13.95% (FCF TTM 377.7m / Revenue TTM 2.71b)
Net Margin = 9.12% (Net Income TTM 247.1m / Revenue TTM 2.71b)
Gross Margin = 71.63% ((Revenue TTM 2.71b - Cost of Revenue TTM 768.3m) / Revenue TTM)
Gross Margin QoQ = 72.54% (prev 72.22%)
Tobins Q-Ratio = 5.33 (Enterprise Value 17.02b / Total Assets 3.19b)
Interest Expense / Debt = 1.87% (Interest Expense 19.6m / Debt 1.05b)
Taxrate = 27.46% (38.5m / 140.2m)
NOPAT = 282.9m (EBIT 390.0m * (1 - 27.46%))
Current Ratio = 2.78 (Total Current Assets 1.89b / Total Current Liabilities 680.1m)
Debt / Equity = 0.69 (Debt 1.05b / totalStockholderEquity, last quarter 1.52b)
Debt / EBITDA = 0.69 (Net Debt 334.7m / EBITDA 486.6m)
Debt / FCF = 0.89 (Net Debt 334.7m / FCF TTM 377.7m)
Total Stockholder Equity = 1.42b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.87% (Net Income 247.1m / Total Assets 3.19b)
RoE = 17.36% (Net Income TTM 247.1m / Total Stockholder Equity 1.42b)
RoCE = 16.57% (EBIT 390.0m / Capital Employed (Equity 1.42b + L.T.Debt 930.8m))
RoIC = 10.52% (NOPAT 282.9m / Invested Capital 2.69b)
WACC = 8.28% (E(16.68b)/V(17.74b) * Re(8.72%) + D(1.05b)/V(17.74b) * Rd(1.87%) * (1-Tc(0.27)))
Discount Rate = 8.72% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.58%
[DCF] Terminal Value 68.94% ; FCFF base≈343.2m ; Y1≈225.3m ; Y5≈102.8m
[DCF] Fair Price = 22.44 (EV 1.91b - Net Debt 334.7m = Equity 1.58b / Shares 70.4m; r=8.28% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 82.16 | EPS CAGR: 40.72% | SUE: -0.09 | # QB: 0
Revenue Correlation: 98.48 | Revenue CAGR: 29.72% | SUE: 1.58 | # QB: 16
EPS next Quarter (2026-06-30): EPS=1.44 | Chg7d=-0.026 | Chg30d=+0.003 | Revisions Net=+4 | Analysts=22
EPS current Year (2026-12-31): EPS=6.35 | Chg7d=+0.010 | Chg30d=+0.166 | Revisions Net=+18 | Growth EPS=+27.7% | Growth Revenue=+22.0%
EPS next Year (2027-12-31): EPS=8.09 | Chg7d=+0.021 | Chg30d=+0.238 | Revisions Net=+18 | Growth EPS=+27.4% | Growth Revenue=+19.1%
[Analyst] Revisions Ratio: +0.22 (11 Up / 7 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 7.3% (Discount Rate 8.7% - Earnings Yield 1.5%)
[Growth] Growth Spread = +14.4% (Analyst 21.6% - Implied 7.3%)